Providing stock analysis for investors of the Canadian junior markets
Bright Minds Biosciences (CSE: DRUG) shared today scientific updates regarding its serotonergic drug pipeline. This includes the announcement of advancing
Read more
Last week, Eight Capital launched coverage on a basket of psychedelic companies. This comes after they produced an industry primer
Read more
On today’s Daily Dive, Cassandra welcomes back Ian McDonald, CEO of Bright Minds Biosciences (CSE: DRUG). He shares the promising
Read more
Bright Minds Biosciences (CSE: DRUG) this morning announced preliminary results from an ongoing study being conducted by the firm. The
Read more
Starting off this week on the Daily Dive is that of Dr Gideon Shapiro, whom is VP of Discovery at
Read more
Bright Minds Biosciences (CSE: DRUG) has an eye for the US big boards. The company this morning announced that it
Read more
Eight Capital recently produced a primer on the psychedelic sector saying that the companies are “poised to fill a growing
Read more
Bright Minds Biosciences Inc. (CSE: DRUG) is a small-cap preclinical biosciences company that is attempting to create the next generation of
Read more
Today on the Daily Dive, our host Cassandra Leah sits down with Ian McDonald, CEO of Bright Minds Biosciences (CSE:
Read more
Bright Minds Biosciences (CSE: DRUG) this morning enhanced its leadership team. The company appointed two industry executives to key roles
Read more